Two companies, Wakefit Innovations and Corona Remedies, are currently offering their Initial Public Offerings (IPOs) for public subscription, providing investors with the opportunity to participate in their listings.
Wakefit Innovations has introduced a book build issue valued at Rs 1,288.89 crores. This includes a fresh issue of 1.93 crore shares totaling Rs 377.18 crores and an offer for sale of 4.68 crore shares amounting to Rs 911.71 crores. The IPO bidding for Wakefit Innovations commenced on December 8, 2025, and is scheduled to close on December 10, 2025. Allotment is anticipated on December 11, with a tentative listing date of December 15 on the BSE and NSE stock exchanges. The price band for the Wakefit Innovations IPO is set between Rs 185 to Rs 195 per share, with a minimum lot size of 76 shares for retail investors, necessitating an investment of Rs 14,820 at the upper price limit.
Conversely, Corona Remedies is offering an IPO worth Rs 655.37 crores, structured solely as an offer for sale of 0.62 crore shares. The bidding for the Corona Remedies IPO also began on December 8, 2025, and will close on December 10, 2025, aligning with Wakefit’s allotment and listing dates of December 11 and December 15, respectively. The price range for the Corona Remedies IPO is higher, ranging from Rs 1,008 to Rs 1,062 per share, with a lot size of 14 shares for retail investors, requiring a minimum investment of Rs 14,868 at the upper end.
In terms of investor interest, Corona Remedies is experiencing stronger demand, with its IPO being oversubscribed at 1.78 times overall as of December 9, 2025. This includes oversubscription of 2.09 times in the retail category and 3.38 times in the non-institutional investor (NII) category. On the other hand, Wakefit Innovations has received a lower overall subscription of 0.23 times, with 1.10 times in the retail category and 0.10 times in the NII category. Notably, Wakefit has not garnered any subscription in the Qualified Institutional Buyers (QIB) category, whereas Corona Remedies has seen some albeit minimal QIB activity.
The grey market premiums (GMP) further emphasize the contrasting reception of the two IPOs. Wakefit Innovations currently exhibits a GMP of Rs 5, suggesting an estimated listing price of Rs 200 per share and an expected gain of 2.56%. In comparison, Corona Remedies has a GMP of Rs 240, indicating a probable listing price of Rs 1,302 per share with an estimated gain of 22.60%.
Analysis from Master Capital Services Ltd. highlights the strategic advantages of both companies in their respective sectors. They mentioned that Wakefit Innovations is well-positioned to capitalize on India’s growing home and furnishings industry due to its integrated business model and diverse product range. On the other hand, Corona Remedies is strategically positioned within the pharmaceutical sector, focusing on women’s healthcare and chronic therapies, poised for growth in the domestic market.
In conclusion, while both IPOs present investment potential, Corona Remedies is currently attracting more market enthusiasm and is anticipated to have a higher premium upon listing. Investors are advised to seek professional guidance before making any investment decisions.